Turn Therapeutics Inc. (TTRX)
| Market Cap | 331.24M +137.8% |
| Revenue (ttm) | n/a |
| Net Income | -8.45M |
| EPS | -0.29 |
| Shares Out | 29.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,385 |
| Open | 10.48 |
| Previous Close | 10.42 |
| Day's Range | 10.28 - 11.55 |
| 52-Week Range | 2.57 - 16.45 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 25.00 (+124.82%) |
| Est. Earnings | Nov 25, 2026 |
About TTRX
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for TTRX stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 124.82% from the latest price.
News
Turn Therapeutics upgraded to Hold from Sell at WBB Securities
WBB Securities upgraded Turn Therapeutics (TTRX) to Hold from Sell with a $10 price target The firm believes the stock is fairly valued following the recent selloff. WBB expects the…
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, tod...
Turn Therapeutics participates in a conference call with BTIG
Biotechnology Analyst Harrison discusses with management on a conference call a program for patient access in Atopic Dermatitis on October 28 at 10 am hosted by BTIG. Published first on…
Turn Therapeutics Proxy statement: Proxy filing
Turn Therapeutics filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Turn Therapeutics initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Turn Therapeutics (TTRX) with a Buy rating and $24 price target The firm cites the potential for GX-03, the company’s non-steroidal topical candidate with possibly…
Turn Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Presenters discussed how trial enrichment strategies and adaptive design can optimize drug labeling and access, especially in atopic dermatitis where current measures exclude some severe cases. Interim results showed significant efficacy using a pruritus-based enrichment approach.
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today ...
Turn Therapeutics appoints Redfield as Chief Scientific Officer
Turn Therapeutics (TTRX) announced the appointment of Robert Redfield, M.D., as Chief Scientific Officer. Dr. Redfield served as the 18th Director of the U.S. Centers for Disease Control and Preventio...
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious ski...
Turn Therapeutics announces publication of peer-reviewed research on GX-03
Turn Therapeutics (TTRX) announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflamma...
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, t...
Turn Therapeutics reports Q2 EPS (20c) vs (5c) last year
“The second quarter was one of the most productive periods in Turn Therapeutics (TTRX)’ history. Our review of interim GX-03 Phase 2 data showed activity across a broader range of…
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious ski...
Turn Therapeutics Earnings release: Q2 2026
Turn Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Turn Therapeutics Quarterly report: Q2 2026
Turn Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, tod...
Turn Therapeutics Slides: Corporate presentation
Turn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Turn Therapeutics Transcript: Study update
GX-03 phase II trial for atopic dermatitis advances to an optimized stage two after interim analysis showed strong efficacy and safety, especially in patients with higher pruritus scores. The study uses a stratified, adaptive design and targets a phase II readout in Q4 2026.
Turn Therapeutics Press release: Study update
Turn Therapeutics issued a press release on July 7, 2026, disclosing material business information to investors.
Turn Therapeutics Slides: Study update
Turn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Turn Therapeutics announces final Stage 2 design of atopic dermatitis program
Turn Therapeutics (TTRX)announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis. The multi-w...
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, to...
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, to...
Turn Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
GX-03, a novel topical therapy, demonstrated strong efficacy and safety in phase II eczema trials, with rapid onset and no adverse events. The company is expanding into toenail fungus and other inflammatory indications, supported by robust IP, a lean operation, and a strong leadership team.
Turn announces interim analysis findings from Phase 2 trial of GX-03
Turn Therapeutics (TTRX) announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating...